基层医疗糖尿病患者持续葡萄糖监测:障碍、促进因素与支持资源
本研究为解释性序列混合方法研究的定性阶段,基于横断面在线调查后对55名美国基层医生和高级执业提供者进行访谈,探讨其处方持续葡萄糖监测(CGM)的障碍与促进因素。结果显示保险和费用障碍最常被提及,距内分泌科超过40英里也是障碍;培训经验和支持人员是促进因素,网络研讨会等资源有助于支持基层处方CGM。
要点
- 保险和费用是基层医生处方CGM的最常见障碍。
- 距内分泌科超过40英里也是CGM处方的障碍因素。
- 培训和员工支持可促进基层CGM处方。
核心结论
- 提高基层医生对CGM使用和益处的理解有助于增强其处方信心。
- 在基层管理CGM可使糖尿病患者受益,尤其是那些难以获得内分泌科服务者。
- 在政策层面解决费用和保险障碍可使CGM更可及并减少糖尿病控制差异。
研究设计与样本
- 解释性序列混合方法研究的定性阶段,遵循横断面在线调查。
- 受访者被邀请参加电话或虚拟访谈,并按距内分泌科距离和处方行为分层。
- 采用快速定性分析理解关系与趋势并识别支持CGM处方的资源。
- 研究设置于两个基层医疗研究网络,对象为美国基层医生和高级执业提供者。
- 共进行55次访谈。
主要发现
- 保险和费用相关障碍最常被提及。
- 距内分泌科超过40英里也是障碍因素。
- 促进因素包括CGM培训和经验以及支持患者教育和保险导航的员工。
- 增加CGM使用和临床结局知识及保险流程指导的资源(如网络研讨会、在线指南、会议)可支持基层处方CGM。
临床怎么用
- 基层医生可借助培训、员工支持和网络研讨会等资源提升CGM处方信心。
- 对难以获得内分泌科服务的患者,可考虑在基层处方和管理CGM。
- 需关注保险和费用障碍,帮助患者导航保险覆盖流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Context: Continuous glucose monitoring (CGM) for patients with type 1 and type 2 diabetes is associated with improved patient health outcomes including reduced glycated hemoglobin (A1c) and hypoglycemia and is part of ADA Standards of Medical Care. CGM prescription often takes place in endocrinology practices. With limited access to endocrinologists, many patients could benefit from receiving CGM through primary care. Objective: The overall study aims to understand primary care clinicians' CGM prescribing experience and likelihood to prescribe, and identify resources needed to support prescribing CGM. This qualitative phase examines barriers and facilitators to prescribing, and resources to support prescribing. Study Design: Qualitative phase of an explanatory sequential mixed-methods study following a cross-sectional online survey. Respondents were invited to participate in phone/virtual interviews to understand CGM prescribing attitudes and behaviors. Participants were stratified based on factors related to distance to an endocrinologist and prescribing behavior. Rapid qualitative analysis was used to understand relationships and trends, and identify resources to support CGM prescription in primary care. Setting: Two primary care research networks. Population studied: Primary care physicians and advanced practice providers in the U.S. Outcome Measures: Resources needed, barriers, and facilitators to prescribing CGM. Results: 55 interviews were conducted. The following themes emerged in the analysis: Insurance and cost-related barriers were most commonly cited, as well as distance to endocrinology when > 40 miles away. Facilitators included training and experience with CGM and staff to support patient education and insurance navigation. Resources (e.g., webinars, online guides, conferences) to increase knowledge about CGM use and clinical outcomes and guidance with insurance processes/coverage could support CGM prescription in primary care. Conclusions: Increased understanding among primary care clinicians of the use and benefits of CGM can help with confidence in prescribing. CGM management in primary care could benefit patients with diabetes, especially those with access barriers to endocrinologists. Addressing cost and insurance barriers at a policy level can make CGM more attainable to underserved populations and reduce disparities in diabetes control.
引用
- Warman M, Fillippi M, Manning B, et al. Continuous glucose monitoring for primary care patients with diabetes: Barriers, facilitators, & resources to support access. Ann Fam Med. 2022. PMID: 36857171. doi:10.1370/afm.20.s1.2689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。